April 15, 2024Open Access

Table S4 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

View Full Paper

Ask AI

Bookmark

Transfection of ASCL1 promotes tolerance to osimertinib by activating distinct upregulated pathways in permissive EGFR mutant lung cancer cells.
Assessment of EGFR mutant cell lines transfected with ASCL1 delineates specific upregulated pathways associated with targeted therapy tolerance.
These identified upregulated pathways highlight cellular mechanisms of drug resistance, though findings remain restricted to in vitro cell models.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Cell line analysis reveals upregulated pathways following ASCL1 transfection in EGFR mutant lung cancer, indicating cellular context drives osimertinib tolerance.

Abstract

Upregulated pathways in EGFR mutant cell lines transfected with ASCL1

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hu et al. (2024) studied this question.

synapsesocial.com/papers/68e6f2a2b6db64358766d0a3 https://doi.org/10.1158/0008-5472.25603576

View Full Paper

Ask AI

Bookmark

Implication

Cell line analysis reveals upregulated pathways following ASCL1 transfection in EGFR mutant lung cancer, indicating cellular context drives osimertinib tolerance.

Abstract

Upregulated pathways in EGFR mutant cell lines transfected with ASCL1

Table S4 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Table S4 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading